BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BioLife Solutions, Inc. (BLFS.OB) Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress


5/23/2013 6:48:56 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOTHELL, Wash., May 23, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the Terrapinn World Stem Cells & Regenerative Medicine Congress 2013 this week in London.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, BioLife's Senior Vice President and Chief Technology Officer, will make a presentation titled "Critical Stability and Biopreservation Considerations for Manufacturing, Storage and Clinical Delivery of Cell and Tissue Products," to the audience of executives and product development managers of commercial regenerative medicine companies. The presentation outlines the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol® storage and shipping media, and CryoStor® cryopreservation freeze media will be presented on relevant cell and tissue types.

Mike Rice, Chief Executive Officer, commented, "We continue to build traction in the high growth regenerative medicine market, and estimate that more than 65 percent of the presenting companies at this conference have adopted our best in class, clinical grade biopreservation media products. A key value-added service we provide, which directly translates into expanded product adoption, is the high quality consulting our team offers to prospective and current customers. Biopreservation outcomes such as cell and tissue shelf life, viability and recovery can greatly impact commercial potential. The combination of the efficacy and quality of our proprietary platform technology, along with our expert technical consulting services, is now recognized and highly valued in the development and commercialization of regenerative medicine products and therapies."

The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications' recently published "Regenerative Medicine Markets" report. BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.

For a list of upcoming events, please visit http://biolifesolutions.com/cell-therapy/category/events/.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced cell damage and death. BioLife's enabling technology provides academic and clinical researchers, and commercial companies significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Relations:

Investor Relations:


Len Hall

Matt Clawson


Allen & Caron Inc

Allen & Caron Inc


(949) 474-4300

(949) 474-4300


len@allencaron.com

matt@allencaron.com





SOURCE BioLife Solutions, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->